Zepp Health Corp (ZEPP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Zepp Health Corp stock (ZEPP) is currently trading at $13.26. Zepp Health Corp PS ratio (Price-to-Sales) is 0.84. Analyst consensus price target for ZEPP is $64.37. WallStSmart rates ZEPP as Sell.
- ZEPP PE ratio analysis and historical PE chart
- ZEPP PS ratio (Price-to-Sales) history and trend
- ZEPP intrinsic value — DCF, Graham Number, EPV models
- ZEPP stock price prediction 2025 2026 2027 2028 2029 2030
- ZEPP fair value vs current price
- ZEPP insider transactions and insider buying
- Is ZEPP undervalued or overvalued?
- Zepp Health Corp financial analysis — revenue, earnings, cash flow
- ZEPP Piotroski F-Score and Altman Z-Score
- ZEPP analyst price target and Smart Rating
Zepp Health Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Zepp Health Corp (ZEPP) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Zepp Health Corp (ZEPP) Key Strengths (4)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Revenue surging 43.00% year-over-year
62.66% held by institutions, strong professional interest
Supporting Valuation Data
Zepp Health Corp (ZEPP) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Earnings declining -68.10%, profits shrinking
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Zepp Health Corp (ZEPP) Detailed Analysis Report
Overall Assessment
This company scores 43/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 4 register as strengths (avg 9.5/10) while 5 fall into concern territory (avg 0.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book, Revenue Growth. Valuation metrics including Price/Sales (0.84), Price/Book (0.93) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 43.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, EPS Growth. Growth concerns include EPS Growth at -68.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -17.20%, Operating Margin at -4.55%, Profit Margin at -15.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -17.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 43.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ZEPP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ZEPP's Price-to-Sales ratio of 0.84x trades 736% above its historical average of 0.1x (94th percentile), historically expensive. The current valuation is 35% below its historical high of 1.29x set in Mar 2026, and Infinity% above its historical low of 0x in Oct 2022. Over the past 12 months, the PS ratio has expanded from ~0.0x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Zepp Health Corp (ZEPP) · TECHNOLOGY › CONSUMER ELECTRONICS
The Big Picture
Zepp Health Corp is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 259M with 43% growth year-over-year. The company is currently unprofitable, posting a -15.5% profit margin.
Key Findings
Revenue growing at 43% YoY, reaching 259M. This pace significantly outperforms most CONSUMER ELECTRONICS peers.
Spending 30% of revenue (77M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -15.5% profit margin. The path to breakeven will be the key catalyst.
Earnings fell 68% YoY while revenue grew 43%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can Zepp Health Corp maintain 43%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.59, so expect amplified moves relative to the broader market.
Sector dynamics: monitor CONSUMER ELECTRONICS industry trends, competitive moves, and regulatory changes that could impact Zepp Health Corp.
Bottom Line
Zepp Health Corp is a high-conviction growth story with revenue accelerating at 43% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -15.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Zepp Health Corp(ZEPP)
NYSE
TECHNOLOGY
CONSUMER ELECTRONICS
China
Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.